BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, February 27, 2026
See today's BioWorld
Home
» Other financings of public biotechnology companies in March 2020
To read the full story,
subscribe
or
sign in
.
Other financings of public biotechnology companies in March 2020
April 3, 2020
Private placements and other private financings of public biopharma companies, including: AB Science, Akari, Armata, Aytu, Baudax, Bellerophon, Biocurepharm, Brainstorm, Bridgebio, Cocrystal, Cytodyn, Emmaus Life Sciences, Enlivex, Equillium, Ethismos Research, Eton, Eyenovia, Helix, Hemostemix, IMV, Isofol Medical, Lattice, Marker, Moberg, Novan, Oncology Venture, Oncoquest, Pacylex, Plx, Predictive Oncology, Propanc, Protalix, Redx, Rockwell Medical, Theravance, Titan, Tonix, Unum, Vaccinex, Vaxart, Vaxil Bio, Verastem, Verrica, Vistagen, Xortx, Zosano.
BioWorld
Analysis and data insight